Biochemical Society

OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

Retrieved on: 
Monday, April 8, 2024
Royal, Medicine, FRS, Biochemical Society, Translational research, Wellcome Sanger Institute, Woman, Drug discovery, Trinity College, Royal Society, International, GSK, University, Membrane, Patient, Doctor of Philosophy, EMBO Gold Medal, University College London, Translation, Architecture, Therapy, Immune system, SAB, The Genetics Society, Molecular biology, Pharmaceutical industry

Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.

Key Points: 
  • Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Sarah Teichmann PhD, FMedSci, FRS to its Scientific Advisory Board (SAB), effective immediately.
  • During this time, she also collaborated with OMass’ co-founder, Professor Dame Carol Robinson, on unraveling the in vivo and in vitro assembly of soluble protein complexes.
  • Ali Jazayeri, Chief Scientific Officer at OMass Therapeutics, commented: “I look forward to working with Sarah.
  • Our previous long-standing collaboration on the assembly of soluble protein complexes demonstrates how her skillset can be complementary to our native mass spectrometry approach and can contribute to further developing our drug discovery platform.”
    Sarah Teichmann, Member of the Scientific Advisory Board of OMass Therapeutics, added: “I am thrilled to be joining OMass Therapeutics’ SAB.

Dr. Sarah Teichmann FmedCci FRS Joins Transition Bio as Scientific Co-Founder

Retrieved on: 
Wednesday, September 22, 2021
Technology, Biotechnology, Nanotechnology, Health, Pharmaceutical, Oncology, Other Science, Research, Software, General Health, Genetics, Science, Data Management, Clinical Trials, Biophysics, Biochemical Society, Distinguished Fellow of the British Computer Society, Artificial intelligence, Research, Computational biology, Wellcome Sanger Institute, Harvard University, OC, EMBO, Medicine, Teichmann, Therapy, Health, Yusuf Hamied Department of Chemistry, Mallinckrodt, Map, Research fellow, Cavendish Laboratory, Physical chemistry, Academy of Medical Sciences (United Kingdom), Laboratory, Gold medal, Fellow, International Society, Biology, Drug design, Genomics, University, Royal Society, Company, EMBO Gold Medal, Disease, Technology, Algorithm, Science, FRCP, Applied physics, Royal, Churchill College, Cambridge, Drug discovery, Transition, Department, FRS, FRSC, Machine learning, Physics, Academy, Management, Pharmaceutical industry

Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.

Key Points: 
  • Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.
  • Dr. Samuel Cohen, a former research fellow in Biophysical Chemistry at the University of Cambridge and visiting fellow at Harvard University, is also a Founder of the Company.
  • Martin commented further, From a scientific leadership and breakthrough innovation standpoint, the combination of our scientific team of doctors Weitz, Knowles, Hyslop, and now Teichmann is as good as it could possibly get.
  • Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis.